申联生物：股东UBI拟减持不超3%股份

Core Viewpoint - UBI, a major shareholder of Shenlian Bio, plans to reduce its stake by up to 3% to fund clinical trials and commercialization of innovative drugs, including an Alzheimer's peptide vaccine [1] Summary by Categories Shareholder Actions - UBI intends to reduce its holdings by a total of up to 12,319,300 shares, which represents 3% of Shenlian Bio's total share capital [1] - The reduction will occur through two methods: a centralized bidding transaction for up to 4,106,400 shares and a block trade for up to 8,212,900 shares [1] Timeline - The planned reduction period is from November 13, 2025, to February 12, 2026 [1] Purpose of Reduction - The funds from the share reduction will be used to support the clinical trials and commercialization of the Alzheimer's peptide vaccine and to accelerate the construction of manufacturing bases in collaboration with partners in China [1]